Among small molecules, plerixafor (CXCR4 antagonist) emerged as the top-ranked candidate, while trofinetide (IGF-1 pathway modulator) achieved the highest ranking among peptides, though both require systematic validation in AD-specific preclinical models before clinical translation. Here, IGF1 is linked to Alzheimer disease.